CAMBRIDGE, Mass., April 30,
2024 /PRNewswire/ -- NeuroBo Pharmaceuticals,
Inc. (Nasdaq: NRBO), a clinical-stage biotechnology
company focused on the transformation of cardiometabolic diseases,
today announced the acceptance of poster presentations for its
promising cardiometabolic assets, DA-1241 and DA-1726, at the EASL
Congress 2024 and the American Diabetes Association (ADA)
84th Scientific Sessions in June.
"Having multiple posters selected for presentation at two of the
most esteemed scientific forums emphasizes the scientific
community's recognition of the compelling pre-clinical data that we
have generated for DA-1241 and DA-1726," stated Hyung Heon Kim, President and Chief Executive
Officer of NeuroBo. "We have completed enrollment for Part 1 of our
Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled
Receptor 119 (GPR119) agonist for the treatment of metabolic
dysfunction-associated steatohepatitis (MASH). Additionally, we
have recently dosed the first patient in the single ascending dose
(SAD) Part 1 of our Phase 1 trial of DA-1726, a novel, dual
oxyntomodulin (OXM) analog agonist that functions as a
glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor
(GCGR) for the treatment of obesity. DA-1726 has consistently
shown, in our preclinical data, to sustain weight loss in
diet-induced obese models by decreasing food consumption and
boosting energy expenditure. Both programs are progressing well,
and we have been able to significantly accelerate the clinical
timelines for DA-1726. We currently expect to both dose the first
patient in the multiple ascending dose (MAD) Part 2 and read-out
top-line data from the SAD Part 1 in the third quarter of 2024,
with top-line data from the MAD Part 2 expected in the first
quarter of 2025."
- June 5-8: EASL Congress
2024. Members of the Dong-A ST Research Center and DA-1241
Phase 2 trial Contract Research Organization (CRO), Gubra, will
present pre-clinical data on DA-1241, in two poster presentations
at this congress in Milan,
Italy.
- Abstract Title: DA-1241, a GPR119 Agonist, Combined
with Semaglutide Synergistically Improved Liver Fibrosis in Mice
with CCl4-Induced Liver Fibrosis
- Authors: Il Hoon Jung,
Tae Hyoung Kim, Sujin Lee, Yuna
Chae, Hyung Heon Kim,
Mi-Kyung Kim
- Presenter Name: II Hoon
Jung, Dong-A ST Research Center
- Abstract Number: 117
- Session: Poster - Fibrosis / Stellate cell biology
- Session Date: Thursday, June 6,
2024
- Session Time: 8:30 am –
6:00 pm CET
-
- Abstract Title: Additive Hepatoprotective Effects of
DA-1241, a Novel GPR119 Agonist, in Combination with Semaglutide in
the GAN Diet-Induced Obese and Biopsy-Confirmed Mouse Model of
MASH
- Authors: Monika Lewinska, Malte
H. Nielsen, Susanne Pors,
Henrik B. Hansen, Il Hoon Jung,
Hyung Heon Kim, Michael Feigh, Mi-Kyung
Kim
- Presenter Name: Dr. Michael
Feigh, Vice President Scientific Research, Gubra
- Abstract Number: 1950
- Session: Poster - MASLD: Experimental and
pathophysiology
- Session Date: Thursday, June 6,
2024
- Session Time: 8:30 am –
6:00 pm CET
- June 21-24: American Diabetes
Association (ADA) 84th Scientific Sessions. A member
of the Dong-A ST Research Center will present pre-clinical data on
DA-1726 in a poster presentation at this scientific session in
Orlando, FL.
- Abstract Title: DA-1726, a GLP1R/GCGR Dual Agonist, A
Promising Approach in Obesity Treatment and Lipid
Management
- Presenter Name: Yuna
Chae, DA-1726 Project Manager, Dong-A ST Research
Center
- Authors: Il-Hun Jung, Tae-Hyoung
Kim, Su Jin Lee, Hyung Heon Kim, Mi-Kyung
Kim, Yuna Chae
- Abstract Number: 2024-LB-5728
- Poster Presentation Number: 2058-LB
- Session: 23-A Obesity-Animal
- Session Date: Saturday, June 22,
2024
- Session Time: 12:30 pm –
1:30 pm ET
After the presentations, the posters will be accessible within
the "Presentations" section of NeuroBo's website at:
https://www.neurobopharma.com/events-presentations/presentations.
About NeuroBo Pharmaceuticals
NeuroBo
Pharmaceuticals, Inc. is a clinical-stage biotechnology
company focused on transforming cardiometabolic
diseases. The company is currently developing DA-1241 for the
treatment of Metabolic Dysfunction-Associated
Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM),
and is developing DA-1726 for the treatment of obesity. DA-1241 is
a novel G-protein-coupled receptor 119 (GPR119) agonist
that promotes the release of key gut peptides GLP-1,
GIP, and PYY. In preclinical studies, DA-1241
demonstrated a positive effect on liver inflammation, lipid
metabolism, weight loss, and glucose metabolism, reducing
hepatic steatosis, hepatic inflammation, and liver
fibrosis, while also improving glucose control. DA-1726 is a
novel oxyntomodulin (OXM) analogue that
functions as a glucagon-like peptide-1 receptor
(GLP1R) and glucagon receptor (GCGR)
dual agonist. OXM is a
naturally-occurring gut hormone that activates GLP1R and
GCGR, thereby decreasing food intake while increasing energy
expenditure, thus potentially resulting in superior body weight
loss compared to selective GLP1R agonists.
For more information, please visit www.neurobopharma.com.
Forward Looking Statements
Certain statements in
this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "believes", "expects", "anticipates", "may",
"will", "should", "seeks", "approximately", "intends", "projects,"
"plans", "estimates" or the negative of these words or other
comparable terminology (as well as other words or expressions
referencing future events, conditions or circumstances) are
intended to identify forward-looking statements. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risks associated
with NeuroBo's ability to execute on its commercial
strategy; the timeline for regulatory submissions; ability to
obtain regulatory approval through the development steps of
NeuroBo's current and future product candidates, the ability
to realize the benefits of the license agreement with Dong-A ST Co.
Ltd., including the impact on future financial and operating
results of NeuroBo; the cooperation of our contract
manufacturers, clinical study partners and others involved in the
development of NeuroBo's current and future product
candidates; potential negative interactions between our product
candidates and any other products with which they are combined for
treatment; NeuroBo's ability to initiate and complete
clinical trials on a timely basis; our ability to recruit subjects
for its clinical trials; whether NeuroBo receives
results from NeuroBo's clinical trials that are
consistent with the results of pre-clinical and previous clinical
trials; impact of costs related to the license agreement, known and
unknown, including costs of any litigation or regulatory actions
relating to the license agreement; effects of changes in applicable
laws or regulations; effects of changes to NeuroBo's
stock price on the terms of the license agreement and any
future fundraising; and other risks and uncertainties described in
our filings with the SEC. Forward-looking statements speak only as
of the date when made. NeuroBo does not assume any
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law.
Contact:
NeuroBo Pharmaceuticals
Marshall
H. Woodworth
Chief Financial
Officer
+1-857-299-1033
marshall.woodworth@neurobopharma.com
Rx Communications Group
Michael
Miller
+1-917-633-6086
mmiller@rxir.com
View original
content:https://www.prnewswire.com/news-releases/neurobo-to-present-latest-pre-clinical-data-on-cardiometabolic-assets-da-1241-and-da-1726-targeting-mash-and-obesity-at-scientific-conferences-in-june-302131193.html
SOURCE NeuroBo Pharmaceuticals, Inc.